Being female, smoking, previous surgeries for IBD, and genetics all tied to higher risk
By Lori Solomon HealthDay Reporter
WEDNESDAY, April 17, 2024 (HealthDay News) — Certain demographic, clinical, and genetic factors heighten the risk for extraintestinal manifestations (EIMs) with inflammatory bowel disease (IBD), according to a study published online March 13 in Gastroenterology.
Michelle Khrom, from Cedars-Sinai Medical Center in Los Angeles, and colleagues investigated the clinical, serologic, and genetic factors associated with EIM complications in IBD. The analysis included 12,083 unrelated individuals with IBD and European ancestry with presence or absence of EIMs (e.g., ankylosing spondylitis, primary sclerosing cholangitis [PSC], peripheral arthritis, and skin and ocular manifestations) across four cohorts.
The researchers found that most EIMs occurred more commonly in women, in those with Crohn disease (especially colonic disease location), and in those who required surgery (both Crohn disease and ulcerative colitis). Risk for EIMs, except for PSC, was higher with smoking. Serologic associations were seen for PSC (immunoglobulin [Ig]G and IgA, perinuclear antinuclear cytoplasmic antibody; anti-Saccharomyces cerevisiae antibodies; and antiflagellin) and any EIM (IgG and IgA, perinuclear antinuclear cytoplasmic antibody; anti-Saccharomyces cerevisiae antibodies; and anti-Pseudomonas fluorescens-associated sequence). Significant genome-wide associations were seen within major histocompatibility complex and CPEB4.
“These inflammatory manifestations outside the gut impact about 40 percent of our patients with IBD,” coauthor Dermot McGovern, M.D., Ph.D., also from Cedars-Sinai, said in a statement. “Our findings will help us identify those at risk of developing these related conditions.”
One author disclosed ties to Merck, Prometheus Biosciences (acquired by Merck), Takeda, and Prometheus Labs.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2024 HealthDay. All rights reserved.
